Edwards Lifesciences logo

Edwards Lifesciences(NYSE) EW

Market Cap$50.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)+6,321%
5 Year-24%
1 Year+17%
1 Month+0%
Premium Feature
Moneyball Superscore
80/100
$88.35
+0.07%
+0.06Today
Edwards Lifesciences last closing stock price
MetricPriceDate
Last closeUSD 88.292026-10-20
Edwards Lifesciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.54%USD 85.272026-10-13
1 month+0.03%USD 88.262026-09-18
3 month+4.65%USD 84.372026-07-22
Year to date+3.57%USD 85.252025-12-31
1 year+17.27%USD 75.292025-10-20
3 year+27.07%USD 69.482023-10-20
5 year-23.72%USD 115.742021-10-21
Since inception+6,321.09%USD 1.382000-03-27

Edwards Lifesciences Financials at a Glance

Market Cap

$50.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.51B

Net Income (TTM)

$1.00B

EPS (TTM)

$1.69

P/E Ratio

52.39

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$88.35

Volume

1,589,462.554

Open

$87.52

Previous Close

$88.29

Daily Range

$87.06 - $89.32

52-Week Range

$74.66 - $96.29

Estimated Earnings Date

Nov 4, 2026

EW News

Medical professional working at a computer terminal

Why Edwards Lifesciences Stock Plummeted Today

Eric VolkmanOct 26, 2023
man with diabetes checking blood sugar levels with wife

3 No-Brainer Medical Device Stocks to Buy Right Now

James HalleyApr 6, 2023
1 big red arrow going down over a stock chart.

Why Edwards Lifesciences Stock Crashed 16% Today

Rich SmithOct 28, 2022
investor sitting at a desk

3 Unstoppable Investments Everyone Needs in Their Portfolio

James BrumleyDec 31, 2021
GettyImages-167612910

Edwards Lifesciences Blows Past Q2 Earnings Estimates

Keith SpeightsJul 24, 2020
Judge signing order behind stethescope and gavel on a table

Abbott Laboratories and Edwards Lifesciences Settle Patent Fight

Eric VolkmanJul 13, 2020
GettyImages-800433994

Could Edwards Lifesciences Be a Millionaire-Maker Stock?

Alex CarchidiJun 27, 2020
GettyImages-638751964

Why Edwards Lifesciences Shares Rose 15.3% in April

Adria CiminoMay 4, 2020
Page 1

EW: Motley Fool Moneyball Superscore

80

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE:EW makes medical devices for heart conditions.

Its products help doctors replace or repair damaged heart valves.

These tools allow for treatments without using open-heart surgery.

What Does Edwards Make?

  • Transcatheter Aortic Valve Replacement: Heart valves used for minimally invasive procedures; generated $2.5 billion in net sales during the first half of 2026.
  • Transcatheter Mitral and Tricuspid Therapies: Systems designed to repair or replace valves for patients with mitral and tricuspid diseases; generated $373.7 million in net sales during the first half of 2026.
  • Surgical Structural Heart: Advanced surgical valves and conduits used in traditional heart surgeries; generated $560.3 million in net sales during the first half of 2026.

New Valves and New Ventures

  • Acquired Autus Valve Technologies in February 2026 for $128.9 million to expand its valve technology portfolio.
  • Sold the Critical Care product group to Becton, Dickinson and Company in September 2024 to focus on structural heart disease.
  • Received United States Food and Drug Administration approval for the SAPIEN 3 transcatheter pulmonic valve in January 2026.
  • Gained CE Mark approval for the SAPIEN M3 RESILIA valve in June 2026 to increase access for European patients.
  • Received FDA approval for TRIFORMIS RESILIA, a surgical tricuspid valve replacement, in May 2026.

A Focus on Heart Innovation

The company manages global operations across the United States, Europe, Japan, and other international regions. It maintains a patient-focused culture that prioritizes clinical evidence and intellectual property for its structural heart technologies.

The Latest Numbers

  • Total net sales were $3.4 billion in the first six months of 2026, up 15.1% year over year.
  • Sales for the Transcatheter Mitral and Tricuspid Therapies group rose 49.6% year over year during the first half of 2026.
  • Net cash provided by operating activities was $695.7 million for the six-month period ended June 30, 2026.
  • The company repurchased 6.9 million shares of its common stock for $558.7 million during the first half of 2026.
  • Research and development expenses increased in the first half of 2026 due to investments in heart failure management.

A Targeted Heart Strategy

Edwards has transitioned into a specialized firm focused on implantable heart innovations by divesting its monitoring and non-core businesses. The company uses clinical data and new product launches to maintain its position in the structural heart market.

AI Generated • Aug 5, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

16,000

CEO

Bernard J. Zovighian, MBA

Website

www.edwards.com

Headquarters

Irvine, CA 92614, US

EW Financials

Key Financial Metrics (TTM)

Gross Margin

77.98%

Operating Margin

28.09%

Net Income Margin

15.43%

Return on Equity

9.69%

Return on Capital

14.82%

Return on Assets

7.25%

Earnings Yield

1.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$50.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

576.40M

Volume

1.59M

Avg. Volume

3.67M

Financials (TTM)

Gross Profit

$5.08B

Operating Income

$1.83B

EBITDA

$1.58B

Operating Cash Flow

$1.72B

Capital Expenditure

-$286.70M

Free Cash Flow

$1.43B

Cash & ST Invst.

$4.25B

Total Debt

$704.40M

Edwards Lifesciences Performance Analysis

Edwards Lifesciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,382,400,0002.9%
20232023-12-31USD 5,010,000,000-6.9%
20242024-12-31USD 5,439,500,0008.6%
20252025-12-31USD 6,067,600,00011.5%
Edwards Lifesciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301.4%
Q42025-12-311.1%
Q12026-03-315.0%
Q22026-06-305.6%
Edwards Lifesciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 2.442.4%
20232023-12-31USD 2.30-5.6%
20242024-12-31USD 1.46-36.6%
20252025-12-31USD 1.8124.0%
Edwards Lifesciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-10.7%
Q42025-12-31-68.0%
Q12026-03-31312.5%
Q22026-06-30-36.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.74B

+13.6%

Gross Profit

$1.35B

+13.5%

Gross Margin

77.56%

N/A

Market Cap

$50.89BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.18M

N/A

Employees

16,000

N/A

Net Income

$241.90M

-26.7%

EBITDA

$562.20M

+40.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$4.25B

+4.7%

Total Debt

$704.40M

+0.3%

Accounts Receivable

$955.70M

+5.9%

Inventory

$1.13B

-0.9%

Long Term Debt

$680.30M

+0.5%

Short Term Debt

$24.10M

-6.9%

Return on Assets

7.25%

N/A

Return on Invested Capital

14.80%

N/A

Free Cash Flow

$585.00M

+142.8%

Operating Cash Flow

$651.90M

+124.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SMMNYSiemens Healthineers AG
$23.38+0.45%
TRUMYTerumo Corporation
$15.12-0.53%
PENPenumbra, Inc.
$323.94-0.12%
GNGBYGetinge AB (publ)
$26.65+1.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$158.24+7.07%
NFLXNetflix
$65.58-4.53%
BITOProShares Trust - ProShares Bitcoin ETF
$11.33+2.86%
SMCISuper Micro Computer
$35.49+9.30%

Questions About EW

What is the current price of Edwards Lifesciences?

Edwards Lifesciences is trading at $88.36 per share.

What is the 52-week range for Edwards Lifesciences?

Over the past 52 weeks, Edwards Lifesciences has traded between $74.66 and $96.29.

How much debt does Edwards Lifesciences have?

As of the most recent reporting period, Edwards Lifesciences reported total debt of $704.40M.

How much cash does Edwards Lifesciences have on hand?

Edwards Lifesciences reported $2.91B in cash and cash equivalents in its most recent financial results.

What is Edwards Lifesciences’s dividend yield?

Edwards Lifesciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services